- Home
- PLUR vs BCAB Comparison
PLUR vs BCAB Comparison
Compare PLUR & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUR
- BCAB
- Stock Information
- Founded
- PLUR 2001
- BCAB 2007
- Country
- PLUR Israel
- BCAB United States
- Employees
- PLUR N/A
- BCAB N/A
- Industry
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- PLUR Health Care
- BCAB Health Care
- Exchange
- PLUR Nasdaq
- BCAB Nasdaq
- Market Cap
- PLUR 24.9M
- BCAB 27.0M
- IPO Year
- PLUR N/A
- BCAB 2020
- Fundamental
- Price
- PLUR $4.66
- BCAB $0.31
- Analyst Decision
- PLUR
- BCAB Buy
- Analyst Count
- PLUR 0
- BCAB 2
- Target Price
- PLUR N/A
- BCAB $5.00
- AVG Volume (30 Days)
- PLUR 7.6K
- BCAB 1.0M
- Earning Date
- PLUR 02-11-2025
- BCAB 03-25-2025
- Dividend Yield
- PLUR N/A
- BCAB N/A
- EPS Growth
- PLUR N/A
- BCAB N/A
- EPS
- PLUR N/A
- BCAB N/A
- Revenue
- PLUR $678,000.00
- BCAB $11,000,000.00
- Revenue This Year
- PLUR N/A
- BCAB N/A
- Revenue Next Year
- PLUR N/A
- BCAB N/A
- P/E Ratio
- PLUR N/A
- BCAB N/A
- Revenue Growth
- PLUR 89.92
- BCAB N/A
- 52 Week Low
- PLUR $4.07
- BCAB $0.24
- 52 Week High
- PLUR $8.48
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- PLUR 53.72
- BCAB 33.57
- Support Level
- PLUR $4.25
- BCAB $0.31
- Resistance Level
- PLUR $4.90
- BCAB $0.36
- Average True Range (ATR)
- PLUR 0.20
- BCAB 0.04
- MACD
- PLUR 0.03
- BCAB 0.01
- Stochastic Oscillator
- PLUR 51.35
- BCAB 31.88
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.